StreetInsider.com News Articles

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

Mon, 26 Oct 2026 07:00:00 -0400

NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2026, on Monday, November 9, 2026, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 10, 2026, to discuss the results and provide a business

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

Mon, 26 Oct 2026 07:00:00 -0400

Form 8-K HARROW, INC. For: Oct 01

Mon, 05 Oct 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20261005/27145723.html

Harrow acquires Tyrvaya nasal spray for dry eye in $100M deal

Mon, 05 Oct 2026 07:01:37 -0400

Harrow (NASDAQ: HROW) has closed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris Inc., according to a statement from the Nashville-based ophthalmic company.

Harrow paid $30 million in cash at closing, funded from cash on hand, and may pay up to an additional $70 million in contingent milestone payments tied to TYRVAYA net sales, for total potential consideration of $100 million. Harrow acquired worldwide rights to TYRVAYA except for Japan, where Viatris retained commercialization rights and agreed to pay Harrow royalties on future net sales.

TYRVAYA is an FDA-approved nasal spray indicated for the treatment of signs and

Harrow Closes Acquisition of TYRVAYA®

Mon, 05 Oct 2026 07:00:00 -0400

NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Viatris retained the rights to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at

Harrow Closes Acquisition of TYRVAYA®

Mon, 05 Oct 2026 07:00:00 -0400

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Wed, 30 Sep 2026 07:00:00 -0400

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings:

American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and
American Academy of Ophthalmology’s (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.

Harrow will have 13 presentations at AAOpt 2026 and two at AAO 2026, spanning dry eye

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Wed, 30 Sep 2026 07:00:00 -0400

American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and
American Academy of Ophthalmology’s (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.

Harrow will have 13 presentations at AAOpt 2026 and two at AAO 2026, spanning dry eye

Leerink Starts Harrow Health (HROW) at Outperform

Wed, 09 Sep 2026 06:09:47 -0400

Leerink analyst Daniel Clark initiates coverage on Harrow Health (NASDAQ: HROW) with a Outperform rating and a price target of $45.00.

For an analyst ratings summary and ratings history on Harrow Health click here. For more ratings news on Harrow Health click here.

Shares of Harrow Health closed at $37.85 yesterday.

Form 144 HARROW, INC. Filed by: Shojaei Amir

Fri, 21 Aug 2026 18:33:00 -0400

si-local-file:///var/storage/secattach/20260821/26962675.html

Form 144 HARROW, INC. Filed by: Shojaei Amir

Fri, 21 Aug 2026 18:33:00 -0400

si-local-file:///var/storage/secattach/20260821/26962675.html

Harrow study shows Iheezo cuts discomfort after eye injections

Thu, 20 Aug 2026 07:04:59 -0400

Harrow (Nasdaq: HROW) announced results from an investigator-initiated study showing that its anesthetic product Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% reduced patient-reported discomfort following intravitreal injections compared with proparacaine ophthalmic solution 0.5%.

The prospective, randomized, contralateral-eye study enrolled 50 adult patients undergoing same-day bilateral intravitreal injections, evaluating 100 eyes across a single private retina practice. Each patient received Iheezo in one randomly assigned eye and proparacaine 0.5% in the fellow eye, with both eyes also receiving 2% lidocaine-soaked pledgets beforehand.

Patients reported approximately 58% less discomfort overall in the Iheezo-treated eye across all four post-injection assessments, measured on a 0-to-10 numeric rating

Harrow study shows Iheezo cuts discomfort after eye injections

Thu, 20 Aug 2026 07:04:59 -0400

Patients reported approximately 58% less discomfort overall in the Iheezo-treated eye across all four post-injection assessments, measured on a 0-to-10 numeric rating

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections